Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website https://jmc.elmerpub.com

Case Report

Volume 16, Number 11, November 2025, pages 444-452

Eccrine Carcinoma Mimicking Breast Cancer: Diagnostic Challenges and Hormone Therapy as an Emerging Treatment

Figures

↓  Figure 1. Histologic features of eccrine carcinoma at the initial diagnosis. Basaloid cells are infiltrating the dermis. (original magnification × 100).
Figure 1.
↓  Figure 2. Immunostain for ER (original magnification × 100). ER: estrogen receptor.
Figure 2.
↓  Figure 3. Immunostain for PR (original magnification × 100). PR: progesterone receptor.
Figure 3.
↓  Figure 4. Immunostain for mammaglobin (original magnification × 100).
Figure 4.
↓  Figure 5. Histologic features of eccrine cell carcinoma at excision. The carcinoma is infiltrative, largely involving the dermis (original magnification × 50).
Figure 5.
↓  Figure 6. Histologic features of eccrine cell carcinoma at excision. (original magnification × 200).
Figure 6.
↓  Figure 7. Histologic features of eccrine cell carcinoma at excision. Extensive perineural invasion. (original magnification × 400).
Figure 7.
↓  Figure 8. Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) scan of the whole body demonstrates increased FDG avidity in (a) left level 1 lymph node, (b) left level 2 lymph node, (c) left internal mammary lymph node, (d) mediastinal/paratracheal lymph node, and (e) left malar soft-tissue nodule (yellow arrows), concerning for metastatic disease. (f) No evidence of increased FDG avidity within the breast tissues to suggest neoplastic disease.
Figure 8.